


# CLAIMS

1. A compound represented by the general formula (I):



(wherein,

$R^1$  and  $R^2$  may be the same or different and each represents an aryl group, heteroaryl group, aryl group substituted with 1 to 3 groups selected from Substituent group  $\alpha$ , or heteroaryl group substituted with 1 to 3 groups selected from Substituent group  $\alpha$ ;

$R^3$  represents any one of the following groups:

- CO- $R^4$ ,
- CO-O- $R^4$ ,
- CO-NH- $R^4$ ,
- CO-CH<sub>2</sub>-N( $R^a$ ) $R^b$ ,
- (CH<sub>2</sub>)<sub>m</sub>-CO- $R^5$ ,
- (CH<sub>2</sub>)<sub>m</sub>- $R^5$ ,
- CO-NH-CO-N( $R^a$ ) $R^b$ ,
- CO-NH-SO<sub>2</sub>-N( $R^a$ ) $R^b$ ,
- CO-NH-CO-(CH<sub>2</sub>)<sub>p</sub>-N( $R^a$ ) $R^b$ , and
- CO-NH<sub>2</sub>;

$R^4$  represents a lower alkyl group, cycloalkyl group, cycloalkyl group substituted with 1 to 3 groups selected from Substituent group  $\alpha$ , lower alkenyl group, lower alkynyl group, halogeno lower alkyl group, hydroxy lower alkyl group, lower alkoxyalkyl group, lower aliphatic acyloxyalkyl group or lower alkoxycarbonylalkyl group;

$R^5$  represents a hydroxyl group, a group -OR<sup>4</sup>, or a

group  $-N(R^a)R^b$ ;

$R^a$  and  $R^b$  may be the same or different and each represents a hydrogen atom, hydroxyl group, lower alkoxy group, hydroxy lower alkoxy group, hydroxy lower alkoxyalkyl group, lower alkoxy lower alkoxyalkyl group, cyano lower alkyl group, cyano lower alkoxyalkyl group, carboxy lower alkyl group, carboxy lower alkoxyalkyl group, lower alkoxycarbonyl lower alkoxyalkyl group, carbamoyl lower alkyl group, carbamoyl lower alkoxyalkyl group, lower aliphatic acylamino lower alkyl group, lower aliphatic acylamino lower alkoxyalkyl group, lower alkylsulfonylamino lower alkyl group, lower alkylsulfonylamino lower alkoxyalkyl group, (N-hydroxy-N-methylcarbamoyl) lower alkyl group, (N-hydroxy-N-methylcarbamoyl) lower alkoxyalkyl group, (N-lower alkoxy-N-methylcarbamoyl) lower alkyl group, (N-lower alkoxy-N-methylcarbamoyl) lower alkoxyalkyl group or  $R^4$ , or together, including the nitrogen atom to which they are attached, represent a nitrogen-containing heterocyclic group or nitrogen-containing heterocyclic group substituted with 1 to 3 groups selected from Substituent group  $\alpha$ ;

m represents an integer of 1 to 6;

A represents a methylene group, carbonyl group or sulfonyl group;

B represents a single bond,  $C_1$ - $C_4$  alkylene group or  $C_2$ - $C_4$  alkenylene group;

D represents an oxygen atom or methylene group;

E represents a  $C_1$ - $C_4$  alkylene group or  $C_2$ - $C_4$  alkenylene group;

n represents an integer of 1 to 3; and,

Substituent group  $\alpha$  represents a group of substituents consisting of halogen atoms, lower alkyl groups, hydroxy lower alkyl groups, halogeno lower alkyl

groups, carboxy lower alkyl groups, lower alkoxy groups, hydroxy lower alkoxy groups, hydroxy lower alkoxyalkyl groups, lower alkoxy carbonyl groups, carboxyl groups, hydroxyl groups, lower aliphatic acyl groups, lower aliphatic acylamino groups, (N-hydroxy-N-methylcarbamoyl) lower alkyl groups, (N-lower alkoxy-N-methylcarbamoyl) lower alkyl groups, hydroxy lower aliphatic acylamino groups, amino groups, carbamoyl groups and cyano groups), or a pharmacologically acceptable salt or other derivative thereof.

2. The compound or pharmacologically acceptable salt thereof according to claim 1, wherein  $R^1$  is an aryl group or an aryl group substituted with 1 to 3 groups selected from Substituent group  $\alpha$ .

3. The compound or pharmacologically acceptable salt thereof according to claim 1, wherein  $R^1$  is phenyl or phenyl substituted with 1 to 3 groups selected from Substituent group  $\alpha$ .

4. The compound or pharmacologically acceptable salt thereof described in claim 1, wherein  $R^1$  is phenyl; or phenyl substituted with 1 to 3 groups selected from the group consisting of halogeno lower alkyl groups, lower alkoxy groups and hydroxyl groups.

5. The compound or pharmacologically acceptable salt thereof according to claim 1, wherein  $R^1$  is phenyl substituted with 1 to 3 groups selected from the group consisting of halogeno lower alkyl groups and lower alkoxy groups.

6. The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R<sup>1</sup> is 3,5-bis(trifluoromethyl)phenyl or 3,4,5-trimethoxyphenyl.
7. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 6, wherein R<sup>2</sup> is an aryl group substituted with 1 to 3 groups selected from Substituent group  $\alpha$ .
8. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 6, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 halogen atoms.
9. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 6, wherein R<sup>2</sup> is 3,4-difluorophenyl or 3,4-dichlorophenyl.
10. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 9, wherein A is a methylene group or carbonyl group.
11. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 9, wherein A is a carbonyl group.
12. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 11, wherein B is a single bond or C<sub>1</sub>-C<sub>4</sub> alkylene group.
13. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 11, wherein B is a single bond.

14. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 13, wherein D is an oxygen atom or a methylene group.

15. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 14, wherein E is a C<sub>1</sub>-C<sub>4</sub> alkylene group.

16. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 14, wherein E is ethylene or trimethylene.

17. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 16, wherein n is 1 or 2.

18. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 16, wherein n is 2.

19. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein R<sup>3</sup> is  $-(CH_2)_m-CO-R^5$ .

20. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein R<sup>3</sup> is  $-CH_2-CO-N(R^a)R^b$ .

21. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein one of R<sup>a</sup> and R<sup>b</sup> represents a hydrogen atom, lower alkyl group, hydroxyl group or lower alkoxy group and the other represents a hydroxy lower alkyl group, hydroxy lower

alkoxyalkyl group, carboxy lower alkyl group, carboxy lower alkoxyalkyl group, lower alkoxy carbonyl lower alkyl group or lower alkoxy carbonyl lower alkoxyalkyl group, or R<sup>a</sup> and R<sup>b</sup> together, including the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group or nitrogen-containing heterocyclic group substituted with 1 to 3 groups selected from Substituent group  $\alpha$ .

22. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein -N(R<sup>a</sup>)R<sup>b</sup> is N-(3-hydroxypropyl)-N-methylamino, N-(4-hydroxybutyl)-N-methylamino, N-(5-hydroxypentyl)-N-methylamino, N-(6-hydroxyhexyl)-N-methylamino, N-[2-(2-hydroxyethoxy)ethyl]-N-methylamino, N-(2-hydroxyethyl)-N-methoxyamino, N-(3-carboxypropyl)-N-methylamino, 2-(3-hydroxypropyl)pyrrolidino, 4-hydroxymethylpiperidino, 4-(2-hydroxyethyl)piperidino, 4-(3-hydroxypropyl)piperidino, 4-(2-hydroxyethoxy)piperidino, 4-(hydroxyacetamido)piperidino, 4-(2-hydroxyethoxymethyl)piperidino or 4-(2-hydroxyethyl)piperazino.

23. A pharmaceutical composition containing, as an active ingredient, a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22.

24. A pharmaceutical composition for the treatment or prophylaxis of diseases mediated by NK<sub>1</sub>, NK<sub>2</sub> and/or NK<sub>3</sub> receptors containing, as an active ingredient, a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22.

25. A pharmaceutical composition for the prophylaxis or

treatment of respiratory diseases, allergic diseases and/or urinary incontinence containing, as an active ingredient, a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22.

26. A pharmaceutical composition for the prophylaxis or treatment of asthma, bronchitis, chronic obstructive lung disease, rhinitis and/or urinary incontinence containing, as an active ingredient, a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22.

27. A pharmaceutical composition for the prophylaxis or treatment of respiratory diseases containing, as an active ingredient, a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22.

28. A pharmaceutical composition for the prophylaxis or treatment of asthma, bronchitis and/or chronic obstructive lung disease containing, as an active ingredient, a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22.

29. The composition according to claim 27 or claim 28 for pulmonary administration.

30. Use of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22, as an active ingredient, for producing a pharmaceutical composition.

31. Use of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22, as an

active ingredient, for producing a pharmaceutical composition for the treatment or prophylaxis of diseases mediated by NK<sub>1</sub>, NK<sub>2</sub> and/or NK<sub>3</sub> receptors.

32. Use of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22, as an active ingredient, for producing a pharmaceutical composition for the prophylaxis or treatment of respiratory diseases, allergic diseases and/or urinary incontinence.

33. Use of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22, as an active ingredient, for producing a pharmaceutical composition for the prophylaxis or treatment of asthma, bronchitis, chronic obstructive lung disease, rhinitis and/or urinary incontinence.

34. Use of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22, as an active ingredient, for producing a pharmaceutical composition for the prophylaxis or treatment of respiratory diseases.

35. Use of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22, as an active ingredient, for producing a pharmaceutical composition for the prophylaxis or treatment of asthma, bronchitis and/or chronic obstructive lung disease.

36. The use according to claim 34 or claim 35, wherein the pharmaceutical composition is for pulmonary administration.



37. A method for preventing or treating diseases mediated by NK<sub>1</sub>, NK<sub>2</sub> and/or NK<sub>3</sub> receptors by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22 to a mammal.

38. A method for preventing or treating respiratory diseases, allergic diseases and/or urinary incontinence by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22 to a mammal.

39. A method for preventing or treating asthma, bronchitis, chronic obstructive lung disease, rhinitis and/or urinary incontinence by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22 to a mammal.

40. A method for preventing or treating respiratory diseases by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22 to a mammal.

41. A method for preventing or treating asthma, bronchitis and/or chronic obstructive lung disease by administering an effective amount of a compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 22 to a mammal.

42. The method according to any one of claims 39 to 40, wherein a compound having the general formula (I) or pharmacologically acceptable salt thereof is administered by pulmonary administration.

43. The method according to any one of claims 37 to 42,  
wherein the mammal is a human.